Oral Drug Shows Clinical Response and Remission in Some Patients
An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the August 16, 2012 issue of the New England Journal of Medicine (NEJM). … Read the full story from the UCSD Newsroom
The principal investigator of the study is Dr. William J. Sandborn, professor of medicine and chief of the Division of Gastroenterology at UCSD. | Read his academic profile | Read his clinical profile
Read the abstract of the study report in the New England Journal of Medicine
Citation of study report: Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16;367(7):616-24.